Posts

Exelixis' TKI falls short in colorectal cancer subgroup as FDA reviews approval in all-comers

Tecentriq Demonstrates Survival Benefit in ctDNA-Guided Bladder Cancer Treatment at ESMO 2025

Exelixis' Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study

Jazz Releases Full Survival Data for Zepzelca in Lung Cancer at ASCO 2025